CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday, April 5, 2017, at 10:40 a.m. ET.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The Company’s oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in immune surveillance. X4’s lead drug candidate (X4P-001) is currently in Phase 2/3 clinical development with the formulation X4P-001-LD for the treatment of patients with a rare, genetic primary immunodeficiency disease, WHIM syndrome, and is in Phase 1/2 clinical development as a potential cancer therapy, for the treatment of patients with refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.